FFAR4 and metabolic syndrome: As illustrated in Figure 7, the current study showed, for the first time, that the synthetic dual GPR40/GPR120 agonist GW9508 alleviated alveolar bone loss and periodontal inflammation in mice with MetS-associated periodontitis.